Investigating the link between FGF23 and cardiovascular damage in anemia and chronic kidney disease.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the cardiovascular alterations associated with increased levels of fibroblast growth factor 23 (FGF23) in patients with anemia, both with and without chronic kidney disease (CKD). It will analyze serum samples from patients to determine the relationship between iron metabolism parameters, FGF23 levels, and markers of cardiovascular damage. The study will include individuals aged 18 and older with specific hemoglobin and serum ferritin levels, while excluding those with certain medical conditions or recent treatments that could affect the results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hemoglobin \< 11g/dl
* Serum ferritin \< 100 ng/ml or transferrin saturation index \< 20%

Exclusion Criteria:

* Weight \< 50 Kg or BMI \< 17
* Acute bleeding \> 500 ml, within 72 hours before study inclusion
* Proliferative hematologic disease. Hemochromatosis
* Active infections within 30 days before study inclusion
* Systemic inflammatory illness
* Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV) infection
* Iron active treatment
* Blood transfusion in the last 90 days before inclusion.
* Cardiovascular hospitalization 30 days before study inclusion
* Anticoagulant treatment with coumarins
* Chronic liver disease
* Immunosuppressive therapy
* Erythropoiesis stimulating agents treatment, radiotherapy or chemiotherapy within 30 days before inclusion
* Scheduled major surgery during study period
* Pregnancy or lactation
* Drugs addiction
* Participation in others clinical trials.

Where it's running

• Hospital Universitario Reina Sofia
  Córdoba, Spain Recruiting

Study contacts

• Principal investigator: Juan Muñoz Castañeda, MD — Maimónides Biomedical Research Institute of Córdoba
• Study coordinator: Casimiro Valle Domínguez, MD
• Email: casimiro.valle.sspa@juntadeandalucia.es
• Phone: 34 957010000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DISC-0974-201 for adults with IBD-related anemia

  This Phase 2 trial will test whether DISC-0974-201 helps adults with inflammatory bowel disease who have anemia driven by inflammation.

  Recruiting at 15 sites Phase 2 Disc Medicine, Inc · Birmingham, Alabama and 14 other locations · NCT07368972

• National registry for people with myelofibrosis and anemia in Germany.

  This project will collect health, treatment, and quality-of-life information from people in Germany with primary or secondary myelofibrosis and anemia to see how their care and symptoms change over time.

  Recruiting iOMEDICO AG · Multiple Locations · NCT06976918

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping

  This project tests a Renal dining map app to help CKD patients in Singapore choose foods when dining out and see if it improves empowerment and well‑being.

  Recruiting Singapore Institute of Technology · Singapore · NCT07804316

• Iron status at ICU discharge in adults with anemia after critical illness

  We are testing whether iron deficiency is common at ICU discharge and whether it relates to how well patients recover after leaving the ICU.

  Recruiting Università degli Studi di Ferrara · Brussels and 3 other locations · NCT07781540

• Self-Management Data and Disease Progression in CKD

  This study tests whether patient-recorded self-management data collected via a mobile app can be linked to CKD progression in adults seen at a university hospital.

  Recruiting Chungnam National University Hospital · Daejeon, DJ · NCT07754097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.